20th Jul 2020 20:02
Arix Bioscience PLC - healthcare investor - Says portfolio company Amplyx Pharmaceuticals announced positive topline data from a phase 2 clinical trial of fosmanogepix as a first-line treatment for patients with invasive fungal infections caused by Candida. The trial met its primary efficacy endpoint, demonstrating a treatment success rate of 80%. Fosmanogepix was well tolerated with no treatment-related serious adverse events or discontinuations.
Current stock price: 86.50 pence
Year-to-date change: down 19%
By Lucy Heming;Â [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
ARIX.L